OM:CAMXPharmaceuticals
How Investors Are Reacting To Camurus (OM:CAMX) Launching Self-Administered Acromegaly Therapy in Germany
Camurus recently announced the launch of Oczyesa®, a long-acting octreotide subcutaneous depot for maintenance treatment of adult acromegaly patients, now made available for the first time in Germany following European Commission marketing authorization.
This marks the introduction of a self-administered therapy for acromegaly in the EU, potentially improving patient convenience and satisfaction while reflecting regulatory momentum for innovative treatments.
We’ll now consider how the EU...